Critical Comparison: T2 Biosystems (TTOO) vs. SurModics (SRDX)
T2 Biosystems (NASDAQ: TTOO) and SurModics (NASDAQ:SRDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
This is a breakdown of current ratings for T2 Biosystems and SurModics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares T2 Biosystems and SurModics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
T2 Biosystems has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, SurModics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Insider & Institutional Ownership
59.8% of T2 Biosystems shares are held by institutional investors. Comparatively, 85.6% of SurModics shares are held by institutional investors. 38.7% of T2 Biosystems shares are held by insiders. Comparatively, 6.4% of SurModics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares T2 Biosystems and SurModics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|T2 Biosystems||$4.10 million||36.27||-$54.80 million||($1.90)||-2.18|
|SurModics||$73.11 million||5.27||$3.92 million||$0.29||101.38|
SurModics has higher revenue and earnings than T2 Biosystems. T2 Biosystems is trading at a lower price-to-earnings ratio than SurModics, indicating that it is currently the more affordable of the two stocks.
SurModics beats T2 Biosystems on 8 of the 13 factors compared between the two stocks.
T2 Biosystems Company Profile
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
SurModics Company Profile
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.